139 results on '"Buxhofer-Ausch V"'
Search Results
2. OC 14.5 Plasma Exchange-free Management of Immune Thrombotic Thrombocytopenic Purpura: The Austrian-German Experience
3. Adverse impact of a high CD4 / CD8 ratio in the allograft may be overcome by methotrexate‐ but not mycophenolate‐ or posttransplant cyclophosphamide‐based graft versus host disease prophylaxis
4. Secreted Mutant Calreticulins As Rogue Cytokines in Myeloproliferative Neoplasms
5. Adverse impact of a high CD4/CD8 ratio in the allograft may be overcome by methotrexate‐ but not mycophenolate‐ or post‐transplant cyclophosphamide‐based graft versus host disease prophylaxis.
6. P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYELOFIBROSIS PATIENTS
7. Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
8. Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
9. Erratum: Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
10. Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients
11. Treatment of acquired thrombotic thrombocytopenic without plasma exchange in selected patients under caplacizumab
12. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria
13. Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab
14. Immature platelet fraction in clinical routine: V815
15. High-dose chemotherapy and autologous haematopoietic stem cell transplantation as adjuvant treatment in early stage and operable breast cancer: retrospective long-term analysis of the European experience: O433
16. Spontaneous changes in tumour cell dissemination to bone marrow in colorectal cancer
17. Neocortical neurones may be targeted by immune attack in anti-Yo paraneoplastic syndrome
18. The detection and significance of minimal residual disease in acute and chronic leukemia
19. PS1470 EFFICACY AND SAFETY OF ANAGRELIDE IN OLDER PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA
20. Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
21. A MULTICENTER EVALUATION OF THE REVISED 2015 WHO MINOR CRITERIA FOR PREFIBROTIC PRIMARY MYELOFIBROSIS
22. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
23. IMPACT OF CALR AND ASXL1 MUTATIONS ON SURVIVAL AND DISEASE COMPLICATIONS IN ESSENTIAL THROMBOCYTHEMIA AND PREFIBROTIC PRIMARY MYELOFIBROSIS STRICTLY DIAGNOSED ACCORDING TO THE WHO-CLASSIFICATION
24. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
25. Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
26. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
27. A prognostic model to predict survival in 867 WHO-defined essential thrombocythemia at diagnosis: a study by the IWG-MRT
28. Development and validation of an International Prognostic Score of thrombosis in WHO-Essential Thrombocythemia (IPSET-thrombosis)
29. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
30. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria
31. Organic Anion Transporting Polypeptide 5A1 (OATP5A1) in Small Cell Lung Cancer (SCLC) Cells: Possible Involvement in Chemoresistance to Satraplatin
32. 6123 Circulating cytokeratin 18 fragments – M30 and M65 – as marker of postoperative residual tumour load in colorectal cancer patients
33. Spontaneous changes in tumour cell dissemination to bone marrow in colorectal cancer
34. Neocortical neurones may be targeted by immune attack in anti‐Yo paraneoplastic syndrome
35. 112 POSTER Multimodal therapy of gastrointestinal stromal tumours (GIST). A review of 24 patients
36. High-dose chemotherapy and autologous haematopoietic stem cell transplantation as adjuvant treatment in early stage and operable breast cancer: retrospective long-term analysis of the European experience
37. A-276 Immunogenic Cell Death (ICD) and ICD-dependent Dendritic Cell Activation triggered by Extracorporeal Photopheresis in CTCL.
38. Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange.
39. Improved Outcomes in Myelofibrosis after Allogeneic Stem-Cell Transplantation in the Era of Ruxolitinib Pretreatment and Intensified Conditioning Regimen-Single-Center Analysis.
40. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
41. Impact of early cyclosporine A levels on acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation using in vivo T-cell depletion.
42. Allogeneic Stem Cell Transplantation in Multiple Myeloma: Risk Factors and Outcomes in the Era of New Therapeutic Options-A Single-Center Experience.
43. BendaEAM versus BEAM as conditioning regimen for ASCT in patients with relapsed lymphoma (BEB): a multicentre, randomised, phase 2 trial.
44. Successful SARS-CoV-2 mRNA Vaccination Program in Allogeneic Hematopoietic Stem Cell Transplant Recipients-A Retrospective Single-Center Analysis.
45. TOP-PIC: a new tool to optimize pharmacotherapy and reduce polypharmacy in patients with incurable cancer.
46. Impact of the Recipient's Pre-Treatment Blood Lymphocyte Count on Intended and Unintended Effects of Anti-T-Lymphocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation.
47. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura.
48. Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms.
49. Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
50. Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.